Altshuler Shaham Ltd Lowers Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Altshuler Shaham Ltd decreased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 11.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 196,263 shares of the company's stock after selling 25,267 shares during the period. Teva Pharmaceutical Industries accounts for about 0.1% of Altshuler Shaham Ltd's portfolio, making the stock its 27th largest holding. Altshuler Shaham Ltd's holdings in Teva Pharmaceutical Industries were worth $4,360,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. Oarsman Capital Inc. acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $29,000. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $66,000. IFP Advisors Inc grew its holdings in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its position in Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Bank of America dropped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Finally, Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded down $0.40 during midday trading on Monday, hitting $13.25. 9,943,602 shares of the company traded hands, compared to its average volume of 9,906,624. The stock has a 50-day moving average of $15.45 and a 200-day moving average of $17.67. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The firm has a market cap of $15.02 billion, a P/E ratio of -9.14, a PEG ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.